MetaCap

ProKidney (PROK) vs Tectonic Therapeutic (TECX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tectonic Therapeutic (TECX) has outperformed ProKidney (PROK) over the past year, gaining 8.1% versus a loss of 52.5%. Over five years, TECX leads with a -57.7% price change compared with -89.5% for PROK. ProKidney is the larger company by market cap ($415.2 million vs $405.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PROK-52.51%TECX+8.08%
+105%+23%-60%
Nov 21, 20251 yearNov 20, 2026
PROK-89.52%TECX-59.45%
+37%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PROK versus TECX key metrics
MetricPROKTECX
Share price$1.04$20.73
Market cap$415.21M$405.26M
1-day change-1.89%-1.47%
YTD return-53.57%-0.62%
1-year return-52.51%+8.08%
5-year return-89.49%-57.66%
EPS (TTM)$-0.61$-4.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$893.00K—
Revenue growth (YoY)+1075.00%—
Net income (latest FY)$-68.99M$-74.15M
Operating margin-18477.83%—
Net margin-7725.20%—
52-week high$2.65$39.53
52-week low$0.87$16.77
Distance from 52-week high-60.75%-47.56%
Analyst consensusbuystrong_buy
Avg. price target upside+525.00%+242.50%
Average volume1.44M212.16K
Shares outstanding209.63M19.55M
Employees23160
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TECX has outperformed PROK by 60.6 percentage points over the past year.

About ProKidney

PROK stock →

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees

About Tectonic Therapeutic

TECX stock →

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

PROK vs TECX FAQ

Which is bigger, ProKidney or Tectonic Therapeutic?

ProKidney (PROK) is larger, with a market capitalization of $415.21M compared with $405.26M for Tectonic Therapeutic (TECX).

Which stock has performed better over the past year, PROK or TECX?

TECX returned +8.08% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.

Are ProKidney and Tectonic Therapeutic in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons